GCLabs

Search for Test Items

Alzheimer disease biomarkers (2 tests)

GC Labs code	W720	Test Field	Immunology

GC Labs code

W720

Test Field

Immunology

Information

Test method	ECLIA (Electrochemiluminescence immunoassay) & calculation
Specimen (mL)	CSF 2.5
Specimen storage	Refrigerated
Specimen stability	Ambient (5 days), Refrigerated (14 days)
Test schedule	Wed
Analytical time (day)	1

Test method

ECLIA (Electrochemiluminescence immunoassay) & calculation

Specimen (mL)

CSF 2.5

Specimen storage

Refrigerated

Specimen stability

Ambient (5 days), Refrigerated (14 days)

Test schedule

Wed

Analytical time (day)

Reference range/Unit	Alzheimer disease biomarkers (2 tests) [CSF,(Cerebrospinal Fluid)] ≤ 0.023 ========================== β-Amyloid (1-42) Phospho-Tau (181P)
Clinical Significance	Alzheimer disease (AD) is the leading form of neurodegenerative disorder, accounting for 70-75% of all dementia, and is pathologically characterized by severe neuronal loss, aggregation of amyloid-ß protein in extracellular senile plaques, and formation of neurofibrillary knots within the nerves composed of hyperphosphorylated tau protein. Clinically, there is a continuum of disease from asymptomatic, focally limited pathologic changes in the brain (years before noticeable symptoms appear) to subtle cognitive changes, mild cognitive impairment, and dementia, with cognitive and functional impairment progressing to progressive loss of independence and symptoms of dementia. Biochemical changes in the cerebrospinal fluid reflect these stage differences. In Alzheimer disease, amyloid beta and tau proteins accumulate in brain tissue, and the concentration of these proteins in the cerebrospinal fluid changes accordingly, and these characteristic changes in concentration can be used to identify the cause of Alzheimer disease.
Compulsory forms
Remark	Collection in a dedicated container is required (FBT, false bottom tube)

Reference range/Unit

Alzheimer disease biomarkers (2 tests)
 [CSF,(Cerebrospinal Fluid)]
≤ 0.023
==========================

β-Amyloid (1-42) 


Phospho-Tau (181P)

Clinical Significance

Alzheimer disease (AD) is the leading form of neurodegenerative disorder, accounting for 70-75% of all dementia, and is pathologically characterized by severe neuronal loss, aggregation of amyloid-ß protein in extracellular senile plaques, and formation of neurofibrillary knots within the nerves composed of hyperphosphorylated tau protein. Clinically, there is a continuum of disease from asymptomatic, focally limited pathologic changes in the brain (years before noticeable symptoms appear) to subtle cognitive changes, mild cognitive impairment, and dementia, with cognitive and functional impairment progressing to progressive loss of independence and symptoms of dementia. Biochemical changes in the cerebrospinal fluid reflect these stage differences. In Alzheimer disease, amyloid beta and tau proteins accumulate in brain tissue, and the concentration of these proteins in the cerebrospinal fluid changes accordingly, and these characteristic changes in concentration can be used to identify the cause of Alzheimer disease.

Compulsory forms

Remark

Collection in a dedicated container is required (FBT, false bottom tube)